关于烟酸的大型试验AIM-NIH报道翻译.docx

美国国立卫生院停止结合胆固醇治疗的临床试验在降低心血管事件上缺乏疗效，促使这个决策生成。AIM-HIGH研究最后更新日期的时间是2011年11月15日新美国医学杂质的研究结果，2011年11月15日（这文章含有很多和AIM-HIGH）研究想关联的文章的网站。The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke. NHLBI已经提前计划18个月停止了研究血脂异常的临床试验，这个实验发现添加高剂量的缓释烟酸治疗心血管病的病人，没有降低心血管事件的风险，包括心脏病和中风。Participants were selected for AIM-HIGH because they were at risk for cardiovascular events despite well-controlled low-density lipoprotein (LDL or bad cholesterol). Their increased risk was due to a history of cardiovascular disease and a combination of low high-density lipoprotein (HDL or good cholesterol) and high triglycerides, another form of fat in the blood. Low HDL and elevated triglycerides are associated with an increased risk of cardiovascular events. While lowering LDL decreases the risk of cardiovascular events, it has not been shown that raising HDL similarly reduces the risk of cardiovascular events. 患者被选为参与AIM-HIGH研究是因为他们有心血管疾病的风险，不考虑有效的控制低密度脂蛋白（LDL或是坏胆固醇）的水平，他们的风险增加是由于心血管病的历史结合低的高密度脂蛋白水平（高密度脂蛋白胆固醇或好胆固醇）和高甘油三脂。另一种形式的血液中的脂肪。低HDL和甘油三酯升高与心血管事件风险增加相关联，并没有证据显示升高HDL能基本和降低LDL水平同等程度的减少心血管事件的风险。During the study’s 32 months of follow-up, participants who took high dose, extended-release niacin and statin treatment had increased HDL cholesterol and lowered triglyceride levels compared to participants who took a statin alone. However, the combination treatment did not reduce fatal or non-fatal heart attacks, strokes, hospitalizations for acute coronary syndrome, or revascularization procedures to improve blood flow in the arteries of the heart and brain.在研究期间32个月的随访期间，使用了高剂量的缓释烟酸和他汀共同治疗增加了高密度脂蛋白胆固醇同事降低了甘油三酯的水平，然而联合治疗并没有减少致命或是非致命的心脏病发作，中风，急性冠状动脉的住院或为提高心脏和脑动脉的血流量进行的血管重